FDA will assess Teva's application for biogeneric Neupogen

02/2/2010 | Reuters

The FDA will evaluate Teva Pharmaceutical Industries' biologics-license application for XM02, a booster of white blood cells and a biosimilar of Amgen's Neupogen. In its filing, Teva stated that it plans to market the drug as Neutroval. The generic-drug maker already markets the treatment in Europe, where a regulatory pathway for biosimilars already exists.

View Full Article in: